Kirkland, QC, October 19, 2026 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today that the Canadian Centre for Veterinary Biologics (CCVB) has approved Nobilis Multriva™ RT+IBm+ND+Gm+REOm for use in poultry. This approval marks the first avian metapneumovirus (aMPV) vaccine approved in Canada. 

Indicated primarily for broiler breeders, this inactivated viral vaccine is indicated for the vaccination of healthy chickens, to reduce egg drop caused by avian metapneumovirus (AMPV), reduce respiratory signs and egg drop caused by infectious bronchitis virus (IBV), reduce mortality and clinical signs caused by Newcastle disease virus (NDV), and provide passive immunity of progeny against disease caused by infectious bursal disease virus (IBDV), and against avian reovirus (ARV). 

“At Merck Animal Health, our commitment to the science of healthier animals includes addressing the significant economic and welfare effects of viral pathogens in broiler breeder flocks,” said Stephen Halley, Business Unit Director, Farm Animals at Merck Animal Health. “This approval gives our customers an innovative option to help protect their birds and support their operations.” 

The vaccine combines aMPV coverage with updated IB strains selected to help extend protection to Mass, 793B, Var2, QX, and Q1 strains. It also includes two ARV strains to support broad protection across genotypes 1–5, along with coverage against classic and variant IBDV strains. 

“Our focus is on delivering practical, science-driven solutions that address the evolving disease landscape,” added Denis Carrier, Associate Director, Scientific Affairs at Merck Animal Health. “This vaccine was designed from the ground up to build and improve on existing formulations.” 

Talk to your veterinarian or to your Merck Animal Health Account Manager for more information on Nobilis Multriva™ RT+IBm+ND+Gm+REOm and consult the label. 

Forward-Looking Statement of Merck &Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. 

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.


The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site  (www.sec.gov).

About Merck Animal Health

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.ca and connect with us on LinkedIn and Facebook.